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Background and objective: Large clinical trials have confirmed the long-term efficacy of 
inhaled corticosteroid/long-acting β
2
-agonist combinations in patients with chronic obstructive 
pulmonary disease (COPD). It was hypothesized that significant treatment effects would already 
be present within 3 months after the initiation of treatment across a range of clinical outcomes, 
irrespective of COPD severity.
Methods: Post hoc analysis of 3-month post-randomization outcomes, including exacerba-
tion rates, dropouts, symptoms, reliever use, and lung function, from three studies with similar 
inclusion criteria of moderate-to-very-severe COPD. Patients (n=1,571) were treated with 
budesonide/formoterol (B/F) 320/9 μg or placebo, twice daily; in one study, tiotropium 18 μg 
once daily was also given.
Results: Over the first 3 months of treatment, fewer patients randomized to B/F experienced 
exacerbations versus the placebo group (111 and 196 patients with $1 exacerbation, respec-
tively). This was true in each COPD severity group. Compared with placebo, B/F treatment led 
to significantly lower 3-month exacerbation rates in the moderate and severe COPD severity 
groups (46% and 57% reduction, respectively), with a nonsignificant reduction (29%) in very 
severe COPD. Fewer dropouts occurred among patients treated with B/F versus placebo, this 
effect being greater with increasing COPD severity. B/F was associated with improved forced 
expiratory volume in 1 s, morning peak expiratory flow rate, total reliever use, and total symp-
tom score versus placebo.
Conclusion: Treatment with B/F decreased exacerbations in patients with moderate-to-
very-severe COPD within 3 months of commencing treatment. This effect was paralleled by 
improved lung function, less reliever medication use, and fewer symptoms, irrespective of 
disease severity.
Keywords: bronchodilator agents, clinical respiratory medicine, clinical trials, COPD
Introduction
Chronic obstructive pulmonary disease (COPD) remains a major cause of ill health 
worldwide and is the third most common cause of death.1,2 In the last decade, a series 
of large clinical trials have provided the evidence base for current drug treatment of 
COPD,3–5 and these findings have been incorporated into treatment guidelines.6 These 
studies resolved many questions about the effect of drugs on individual outcomes. 
However, there are limited data that indicate how quickly improvement becomes 
evident following the initiation of treatment, and that describes the factors that influ-
ence early responses to treatment.
In many COPD trials lasting $1 year, the first clinical visit occurred 3 months 
after randomization, but results are reported for the whole study duration.3,7 Analysis 
of diary-card data from the initial long-acting β
2
-agonist (LABA) and inhaled 
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corticosteroid (ICS) trials in COPD established that treatment 
improves peak expiratory flow (PEF) rate and symptoms 
within 2 weeks of initiation, a change that was more rapid 
when the LABA and ICS were given together.8,9 However, 
the early impact of treatment on exacerbations and disease 
control, that is, within 3 months of randomization, was not 
formally evaluated in these trials. Additionally, in many 
studies, the impact of disease severity on response to treat-
ment was not considered, for instance, in the 3-month CLIMB 
study in which patients received budesonide/formoterol in 
addition to tiotropium.10 The effect of disease severity was 
assessed in patients receiving salmeterol and fluticasone 
propionate, alone or in combination, in the TORCH study, 
where worse disease severity as assessed by spirometry was 
associated with a greater likelihood of having an exacerbation 
but was not related to the overall treatment effects.11
It was hypothesized that significant treatment effects 
would be present across a range of clinical outcomes within 
3 months of budesonide/formoterol (B/F) initiation and that 
these differences would be independent of the severity of 
spirometric impairment. To test these hypotheses, data were 
pooled from three previously reported studies confirming the 
efficacy of the ICS/LABA B/F in patients with COPD.9,10,12
Methods
study design
A post hoc analysis of 3-month data from three studies of 
patients with moderate-to-very-severe COPD is reported; 
complete details of these studies are reported elsewhere.9,10,12 
The studies recruited outpatients aged $40 years with $10 
pack-years smoking history, COPD symptoms for $2 years, 
forced expiratory volume in 1 s (FEV
1
)/vital capacity (VC) 
ratio #70%, pre-bronchodilator FEV
1
 #50% predicted, and 
history of $1 COPD exacerbation within 1–12 months of 
inclusion. All participants provided written informed con-
sent. Ethical approval was obtained for each of the studies 
included in this analysis9,10,12 from local Independent Ethics 
Committees in each of the participating countries.
This analysis included patients treated with B/F 
(Symbicort® Turbuhaler®; AstraZeneca, Sweden) 320/9 μg 
twice daily (two inhalations of 160/4.5 μg9,12 or one inhalation 
of 320/9 μg10) or placebo twice daily. In the CLIMB study,10 
study medications were given in addition to tiotropium 
18 μg once daily. As-needed terbutaline 0.5 mg/inhalation 
(Bricanyl® Turbuhaler®; AstraZeneca) was permitted as 
reliever medication throughout all the studies.
Spirometric severity of COPD was classified as moder-
ate (,80% to $50% predicted), severe (,50% to $30% 
predicted), or very severe (,30% predicted), according to 
GOLD 2016 post-bronchodilator FEV
1
 grading criteria.6
Study variables
In the studies included in this post hoc analysis, exacerba-
tions were defined as worsening of COPD leading to oral 
corticosteroids, alone or in combination with antibiotics, 
and/or hospitalization/emergency room visits. Exacerbations 
leading to antibiotics alone from two studies9,12 were excluded 
from the analysis in order to achieve a common definition of 
exacerbations. The number of patients who dropped out from 
the studies (for any reason, including exacerbations) was also 
recorded. Lung function was recorded as pre-dose FEV
1
 (L) 
at study visits (at weeks 1, 6, and 1210 or at months 1, 2, 
and 39,12), and daily morning PEF (L/min) was collected from 
electronic diaries10 or diary cards9,12 of the patients. Reliever 
medication use (inhalations/day) and symptoms of dyspnea, 
cough, chest tightness, and night time awakenings (assessed 
on a 5-point scale; 0–4, where 4= severe symptoms) were also 
recorded in patient diaries and collected at clinic visits.
statistical methods
Patient demographics and baseline characteristics are pre-
sented descriptively. All variables were analyzed by disease 
severity and treatment. The 3-month rates of exacerbations 
were assessed using Poisson regression analysis, with study 
and treatment as factors, and the number of days in the study 
as an offset variable. Over-dispersion was assessed in each 
model by calculating the ratio of the model deviance to its 
number of degrees of freedom. These analyses utilized only 
actual recorded data and did not impute for missing data. The 
rate (and rate ratios [RR]) of exacerbations within 3 months 
and corresponding 95% confidence intervals (CIs) were 
presented. Percentage reductions in exacerbation rates with 
B/F versus placebo were also presented, which were derived 
from the rate ratio. The number of patients with at least one 
exacerbation and dropouts were presented descriptively. 
Subsequent analyses included change from baseline in 
FEV
1
 (L), morning PEF (L/min), reliever use (inhala-
tions/day), and total symptom scores and were analyzed using 
analysis of covariance to estimate the treatment differences 
between B/F and placebo by COPD severity group. Least 
squared means and differences in least squared means with 
corresponding 95% CIs were presented.
sensitivity analyses
In addition to the 3-month analyses, the same statistical 
methods were applied at 12 months using data from the two 
12-month studies.9,12
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Results
Patient demographics and clinical 
characteristics
In total, 1,571 patients who received B/F or placebo were 
identified. Patient flow through the three studies and inclu-
sion in this analysis is shown in Figure 1. Of these, 654 
were from the CLIMB study10 and received background 
tiotropium. Six patients with missing FEV
1
 data and six 
patients with post-bronchodilator FEV
1
 .80% predicted 
were excluded from all analyses. The mean age of patients 
was 63.7 years, and 76.6% were male. COPD severity was 
moderate in 377 (24.0%), severe in 962 (61.2%), and very 
severe in 232 (14.8%) patients, according to GOLD 2016 
criteria.6 Patient demographics and baseline clinical charac-
teristics, by treatment and COPD severity, are summarized 
in Table 1. Lung function reversibility (% predicted) was 
higher in those with moderate COPD (10.4%–11.3%) than 
in those with severe and very severe COPD (4.1% and 
2.5%, respectively, Table 1). Baseline characteristics for the 
917 patients included in the 12-month sensitivity analysis are 
summarized in Table S1, and the characteristics by study of 
all the patients are summarized in Table S2.
Exacerbations
By 3 months, 111 (14.2%) B/F-treated patients and 196 
(25.1%) patients in the placebo group had experienced at least 
one exacerbation (Table 2). B/F treatment for 3 months was 
associated with lower exacerbation rates (moderate COPD: 
0.17 [95% CI 0.12, 0.24]; severe COPD: 0.16 [95% CI 0.13, 
0.21]; very severe COPD: 0.27 [95% CI 0.19, 0.39]) than 
placebo (moderate COPD: 0.32 [95% CI 0.24, 0.42]; severe 
COPD: 0.38 [95% CI 0.33, 0.45]; very severe COPD: 0.38 
[95% CI 0.28, 0.53]). Corresponding exacerbation rate reduc-
tions with B/F compared with placebo were significant for 
moderate (reduction: 46%; RR: 0.54; P=0.005) and severe 
(reduction: 57%; RR: 0.43; P,0.0001) COPD, although they 
were not statistically significant in the very severe COPD 
group (reduction: 29%; RR: 0.71; P=0.153) (Figure 2). 
There were more patients without exacerbations in the B/F 
than placebo group (85.8% vs 75.0%), and the proportion 
of patients with 1, 2, or $3 exacerbations was reduced in 
B/F-treated patients (Figure S1).
At 12 months, 168 (36.8%) B/F-treated patients and 195 
(43.0%) patients in the placebo group had experienced at least 
one exacerbation (Table 3). B/F was associated with signifi-
cantly lower exacerbation rates compared with placebo in 
patients with moderate (reduction: 43%; RR: 0.57; P=0.001) 
and severe (reduction: 38%; RR: 0.62; P,0.0001) COPD, 
although rate reductions were not statistically significant in 
patients with very severe COPD (reduction: 7%; RR: 0.93; 
P=0.674, Figure 3).
Dropouts
Overall, 215 (13.7%) and 320 (35.2%) patients dropped out 
of the combined 3-month and 12-month study populations, 
respectively. There were fewer dropouts with B/F than 
placebo at 3 months (n=81 [10.4%] vs 134 [17.1%]; Table 2) 
and 12 months (n=129 [28.3%] vs 191 [42.1%]; Table 3). 
In general, the proportion of dropouts increased with increas-
ing disease severity for both treatments at 3 and 12 months; 
fewer patients who received B/F than placebo dropped out 
in all three COPD severity groups (Tables 2 and 3).
lung function, reliever use, and COPD 
symptoms
B/F was associated with a greater effect on FEV
1
 than 
placebo, irrespective of COPD severity (Figure 4A). The 
change from baseline in FEV
1
 (L) after 3 months treatment 
with B/F was 0.16 (95% CI 0.13, 0.19), 0.10 (95% CI 0.08, 
0.12), and 0.09 (95% CI 0.06, 0.12) in moderate, severe, and 
very severe COPD, respectively. The corresponding values 
for placebo were -0.03 (95% CI -0.07, 0.00), -0.04 (95% 
CI -0.06, -0.02), and 0.01 (95% CI -0.03, 0.04).
B/F also demonstrated a greater effect on morning PEF 
than placebo (Figure 4B). Changes in morning PEF (L/min) 
after 3 months treatment with B/F were 15.1 (95% CI 10.6, 
19.5), 7.6 (95% CI 4.9, 10.2), and 11.1 (95% CI 6.9, 15.4) 
in moderate, severe, and very severe COPD, respectively. 
Corresponding values for placebo were -4.3 (95% CI -9.0, 
0.3), -6.8 (95% CI -9.4, -4.2), and 1.1 (95% CI -3.2, 5.4). The 
improvement with B/F versus placebo was greater in patients 
with moderate and severe COPD than very severe disease.
B/F-treated patients reported significantly less reliever 
use than patients in the placebo group, irrespective of 
COPD severity (all P,0.0001, Figure 4C). The change 
from baseline in total reliever use (inhalations/day) after 
3 months treatment with B/F versus placebo was -0.66 (95% 
CI -0.94, -0.38), -0.77 (95% CI -0.99, -0.55), and -1.50 
(95% CI -2.03, -0.97) in moderate, severe, and very severe 
COPD, respectively. The cohort of patients with very 
severe COPD, who experienced the greatest improvement 
relative to placebo, had the highest reliever use at baseline 
(4.00 and 5.07 inhalations/day in the B/F and placebo arms, 
respectively).
Compared with placebo, B/F was also associated with 
a statistically significant improvement from baseline in the 
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total symptom score, irrespective of COPD severity (all 
P,0.0001, Figure 4D). The change from baseline in total 
symptom score after 3 months treatment with B/F was -1.23 
(95% CI -1.46, -0.99), -0.57 (95% CI -0.73, -0.41), 
and -0.92 (95% CI -1.28, -0.56) in moderate, severe, and 
very severe COPD, respectively. The corresponding values 
for placebo were -0.26 (95% CI -0.51, -0.01), -0.04 (95% 
CI -0.19, 0.11), and 0.34 (95% CI -0.03, 0.70).
safety
Pooled analysis of adverse events (AEs) and serious AEs 
across the three studies found no difference between B/F and 
placebo after 3 and 12 months treatment, while the number of 
discontinuations due to an AE was lower in B/F-treated than 
placebo-treated patients at both 3 months (5.8% vs 11.5%) 
and 12 months (17.5% vs 25.8%) (Tables S3 and S4, respec-
tively). Ten patients in each treatment group (2.2%) had a 
fatal AE. Pooled analysis of the most frequently reported 
AEs in each treatment group after 3 and 12 months treatment 
are summarized in Tables S5 and S6. At 3 months, the most 
frequently reported AEs were COPD (7.1% B/F vs 13.0% 
placebo), nasopharyngitis (3.8% vs 3.3%), and headache 
(1.5% vs 0.9%).
Discussion
Previous analyses have shown that ICS/LABA combina-
tions produce improvements in a range of clinical outcomes 
versus placebo, including prolonged time to first exacerba-
tion, improved lung function, and improved health-related 
quality of life.9,12–14 These improved outcomes are greater 
with ICS/LABA combinations than with either agent alone T
ab
le
 1
 P
at
ie
nt
 d
em
og
ra
ph
ic
s 
an
d 
ba
se
lin
e 
cl
in
ic
al
 c
ha
ra
ct
er
is
tic
s,
 b
y 
di
se
as
e 
se
ve
ri
ty
 a
nd
 t
re
at
m
en
t 
(3
-m
on
th
 d
at
a 
se
t: 
C
al
ve
rl
ey
 e
t 
al
, S
za
fr
an
sk
i e
t 
al
, a
nd
 C
LI
M
B 
st
ud
ie
s)
9,
10
,1
2
C
ha
ra
ct
er
is
ti
c
A
ll 
pa
ti
en
ts
(n
=1
,5
71
)
B
/F
P
la
ce
bo
M
od
er
at
e 
C
O
P
D
(n
=1
99
)
Se
ve
re
  
C
O
P
D
(n
=4
69
)
V
er
y 
se
ve
re
 
C
O
P
D
(n
=1
18
)
A
ll 
pa
ti
en
ts
(n
=7
86
)
M
od
er
at
e 
C
O
P
D
(n
=1
78
)
Se
ve
re
  
C
O
P
D
(n
=4
93
)
V
er
y 
se
ve
re
 
C
O
P
D
(n
=1
14
)
A
ll 
pa
ti
en
ts
(n
=7
85
)
a
ge
, y
ea
rs
63
.7
 (
8.
9)
62
.8
 (
9.
4)
63
.9
 (
8.
9)
63
.1
 (
7.
9)
63
.5
 (
8.
9)
63
.5
 (
9.
4)
64
.3
 (
8.
8)
62
.8
 (
8.
1)
63
.9
 (
8.
9)
M
al
e,
 n
 (
%
)
1,
20
4 
(7
6.
6)
12
7 
(6
3.
8)
37
0 
(7
8.
9)
10
6 
(8
9.
8)
60
3 
(7
6.
7)
12
2 
(6
8.
5)
38
4 
(7
7.
9)
95
 (
83
.3
)
60
1 
(7
6.
6)
lu
ng
 fu
nc
tio
n
Pr
e-
br
on
ch
od
ila
to
r 
FE
V
1, 
l
1.
13
 (
0.
42
)
1.
42
 (
0.
49
)
1.
11
 (
0.
34
)
0.
72
 (
0.
24
)
1.
13
 (
0.
43
)
1.
46
 (
0.
41
)
1.
10
 (
0.
34
)
0.
72
 (
0.
22
)
1.
12
 (
0.
41
)
R
ev
er
si
bi
lit
y,
 %
 p
re
di
ct
ed
5.
51
 (
5.
83
)
11
.3
0 
(7
.6
8)
4.
09
 (
4.
07
)
2.
50
 (
2.
98
)
5.
67
 (
6.
09
)
10
.4
1 
(6
.5
1)
4.
15
 (
4.
39
)
2.
52
 (
2.
95
)
5.
34
 (
5.
55
)
Po
st
-b
ro
nc
ho
di
la
to
r 
FE
V
1, 
%
 p
re
di
ct
ed
a
42
.4
 (
3.
2–
79
.5
)
54
.8
 (
50
.0
–7
6.
6)
41
.5
 (
30
.1
–5
0.
0)
25
.2
 (
3.
2–
30
.0
)
42
.8
 (
3.
2–
76
.6
)
54
.6
 (
50
.0
–7
9.
5)
40
.5
 (
30
.0
–4
9.
9)
25
.9
 (
15
.8
–3
0.
0)
42
.0
 (
15
.8
–7
9.
5)
Pr
e-
br
on
ch
od
ila
to
r 
 
Fe
V
1/
V
C
b  r
at
io
, %
a
45
.6
 (
15
.7
–1
08
.4
)
53
.7
 (
27
.7
–8
6.
7)
43
.7
 (
20
.2
–8
7.
0)
31
.4
 (
15
.7
–9
3.
4)
45
.2
 (
15
.7
–9
3.
4)
54
.7
 (
27
.9
–1
08
.4
)
45
.4
 (
21
.6
–8
5.
5)
34
.0
 (
19
.6
–6
5.
3)
45
.9
 (
19
.6
–1
08
.4
)
sm
ok
in
g 
hi
st
or
y,
 p
ac
k-
ye
ar
sa
38
.0
 (
10
.0
–2
80
.0
)
35
.0
 (
10
.0
–1
60
.0
)
38
.0
 (
10
.0
–2
80
.0
)
38
.5
 (
10
.0
–1
32
.0
)
37
.0
 (
10
.0
–2
80
.0
)
35
.0
 (
10
.0
–1
50
.0
)
40
.0
 (
10
.0
–1
56
.0
)
37
.0
 (
10
.0
–1
60
.0
)
39
.0
 (
10
.0
–1
60
.0
)
sg
r
Q
 t
ot
al
 s
co
re
56
.3
4 
(1
8.
92
)
53
.5
7 
(1
9.
25
)
55
.8
9 
(1
8.
58
)
59
.4
3 
(1
8.
39
)
55
.7
9 
(1
8.
79
)
56
.3
2 
(2
1.
30
)
56
.4
9 
(1
8.
30
)
59
.5
6 
(1
8.
45
)
56
.8
9 
(1
9.
05
)
R
el
ie
ve
r 
us
e,
 in
ha
la
tio
ns
/d
ay
3.
40
 (
3.
12
)
2.
86
 (
2.
65
)
3.
42
 (
2.
95
)
4.
00
 (
3.
15
)
3.
37
 (
2.
93
)
2.
63
 (
2.
40
)
3.
34
 (
3.
16
)
5.
07
 (
4.
45
)
3.
43
 (
3.
31
)
N
ot
es
: D
at
a 
pr
es
en
te
d 
as
 a
ri
th
m
et
ic
 m
ea
n 
(s
ta
nd
ar
d 
de
vi
at
io
n)
 u
nl
es
s 
ot
he
rw
is
e 
st
at
ed
. a
D
at
a 
ar
e 
m
ed
ia
n 
(r
an
ge
). 
b F
V
C
 in
 o
ne
 s
tu
dy
10
 a
nd
 V
C
 in
 tw
o 
st
ud
ie
s.
9,
12
 M
od
er
at
e 
C
O
PD
 w
as
 d
efi
ne
d 
as
 p
os
t-
br
on
ch
od
ila
to
r 
FE
V
1 8
0%
–5
0%
 p
re
di
ct
ed
, 
se
ve
re
 C
O
PD
 a
s 
po
st
-b
ro
nc
ho
di
la
to
r 
FE
V
1 
50
%
–3
0%
 p
re
di
ct
ed
, a
nd
 v
er
y 
se
ve
re
 C
O
PD
 a
s 
po
st
-b
ro
nc
ho
di
la
to
r 
FE
V
1 ,
30
%
 p
re
di
ct
ed
.
A
bb
re
vi
at
io
ns
: B
/F
, b
ud
es
on
id
e/
fo
rm
ot
er
ol
; C
O
PD
, c
hr
on
ic
 o
bs
tr
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e;
 F
EV
1, 
fo
rc
ed
 e
xp
ir
at
or
y 
vo
lu
m
e 
in
 1
 s
; F
V
C
, f
or
ce
d 
vi
ta
l c
ap
ac
ity
; s
g
r
Q
, s
t 
g
eo
rg
e’
s 
r
es
pi
ra
to
ry
 Q
ue
st
io
nn
ai
re
; V
C
, v
ita
l c
ap
ac
ity
.
Table 2 Number of patients with at least one exacerbation 
and dropouts by disease severity in the 3-month data set 
(Calverley et al, szafranski et al, and ClIMB studies)9,10,12
Patients, n (%) B/F
Moderate
(n=196)
Severe
(n=469)
Very severe
(n=117)
Alla
(n=782)
COPD exacerbation 24 (12.2) 60 (12.8) 27 (23.1) 111 (14.2)
Dropout 20 (10.2) 47 (10.0) 14 (12.0) 81 (10.4)
Placebo
Moderate
(n=178)
Severe
(n=492)
Very severe
(n=112)
Alla
(n=782)
COPD exacerbation 44 (24.7) 122 (24.8) 30 (26.8) 196 (25.1)
Dropout 28 (15.7) 81 (16.5) 25 (22.3) 134 (17.1)
Notes: aThe 3-month data set includes 3-month data from the two 12-month 
studies9,12 as well as that from the 3-month study.10 ITT population includes only 
patients analyzed for exacerbations (n=1,564). Moderate COPD was defined as post-
bronchodilator FEV1 80%–50% predicted, severe COPD as post-bronchodilator FEV1 
50%–30% predicted, and very severe COPD as post-bronchodilator FEV1 ,30% 
predicted.
Abbreviations: B/F, budesonide/formoterol; COPD, chronic obstructive pulmo-
nary disease; FeV1, forced expiratory volume in 1 s.
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at 12 months. ICS/LABA combinations can be used either 
as a primary treatment9,12–15 or in addition to therapy with 
a long-acting antimuscarinic agent in the management of 
severe COPD.10 However, the early effects (within the first 
3 months) of ICS/LABA following treatment initiation are 
less well understood. This study investigated the early effects 
of this combination compared with placebo when used either 
alone9,12 or in addition to tiotropium10 in different COPD 
severities. Of clinical relevance, the beneficial effects of B/F 
compared with placebo on exacerbations were evident within 
3 months of treatment and were paralleled by improved lung 
function, reduced need for reliever use, and fewer symptoms 
compared with placebo, irrespective of the severity of COPD. 
The beneficial effects of B/F on exacerbation rate, lung func-
tion, symptoms, and health-related quality of life have been 
reported previously in comparison with both budesonide and 
formoterol alone.9,12
In the three studies included in the analysis,9,10,12 exacerba-
tion rate was assessed in patients with COPD who would fall 
within grades B, C, and D of the new GOLD classification.6 
Conventionally, exacerbations are defined by health care 
utilization and are reported over 1 year, which increases the 
number of events and, hence, the statistical power to detect 
any difference between treatments. This analysis focused on 
the first 3 months of treatment, thus reducing the total number 
of exacerbation events. Despite this, one-quarter of those ran-
domized to placebo reported at least one event, and this was 
significantly more than that seen with combination treatment. 
Although more patients dropped out in the placebo arm than 
in the active treatment group, our analyses still had sufficient 
power to detect treatment-related differences, not only for 
exacerbation rates, but in lung function improvement, reliever 
use, and self-reported symptoms.
A consistent reduction in the exacerbation rate over the 
first 3 months of treatment was observed in patients with 
spirometrically defined moderate or severe disease. Although 
there were proportionally more exacerbations in patients with 
very severe disease, more patients in this group dropped out, 
which may explain the lack of treatment effect observed. The 
effect of differential withdrawal on treatment effect has been 
described previously16 and merits further study.
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Figure 2 (A) 3-month exacerbation rates in patients with moderate, severe, and very severe COPD receiving B/F or placebo; and (B) 3-month exacerbation rate ratios 
between B/F and placebo, by disease severity. Vertical lines represent 95% confidence intervals. Moderate COPD was defined as post-bronchodilator FEV1 80%–50% 
predicted, severe COPD as post-bronchodilator FEV1 50%–30% predicted, and very severe COPD as post-bronchodilator FEV1 ,30% predicted, according to gOlD 2016 
criteria (3-month data set; Calverley et al, szafranski et al, and ClIMB studies).9,10,12
Abbreviations: B/F, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s.
Table 3 Number of patients with at least one exacerbation and 
dropouts by disease severity in the 12-month data set (12-month 
data set; Calverley et al, and szafranski et al studies only)9,12
Patients, n (%) B/F
Moderate
(n=106)
Severe
(n=266)
Very severe
(n=84)
Alla
(n=456)
COPD exacerbation 30 (28.3) 96 (36.1) 42 (50.0) 168 (36.8)
Dropout 22 (20.8) 80 (30.1) 27 (32.1) 129 (28.3)
Placebo
Moderate
(n=108)
Severe
(n=275)
Very severe
(n=71)
Alla
(n=454)
COPD exacerbation 43 (39.8) 121 (44.0) 31 (43.7) 195 (43.0)
Dropout 41 (38.0) 115 (41.8) 35 (49.3) 191 (42.1)
Notes: aThe 12-month data set includes data from the two 12-month studies.9,12 
ITT population includes only patients analyzed for exacerbations (n=910). Moderate 
COPD was defined as post-bronchodilator FEV1 80%–50% predicted, severe COPD 
as post-bronchodilator FEV1 50%–30% predicted, and very severe COPD as post-
bronchodilator FEV1 ,30% predicted.
Abbreviations: B/F, budesonide/formoterol; COPD, chronic obstructive pulmo-
nary disease; FeV1, forced expiratory volume in 1 s.
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Figure 4 Difference in the mean change from baseline in (A) FeV1; (B) morning PeF; (C) daily reliever use; and (D) symptom score between B/F and placebo, by disease 
severity. Vertical lines represent 95% confidence intervals. Moderate COPD was defined as FEV1 80%–50% predicted, severe COPD as FeV1 50%–30% predicted, and very 
severe COPD as FeV1 ,30% predicted, according to gOlD 2016 criteria (3-month data set; Calverley et al, szafranski et al, and ClIMB studies).
9,10,12
Abbreviations: B/F, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; inh, inhalations; mPeF, morning peak 
expiratory flow rate.
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Figure 3 (A) Annual exacerbation rates in patients with moderate, severe, and very severe COPD receiving B/F or placebo and (B) annual exacerbation rate ratios between 
B/F and placebo, by disease severity. Vertical lines represent 95% confidence intervals. Moderate COPD was defined as FEV1 80%–50% predicted, severe COPD as FeV1 50%–
30% predicted, and very severe COPD as FeV1 ,30% predicted, according to gOlD 2016 criteria (12-month data set; Calverley et al and szafranski et al studies only).
9,12
Abbreviations: B/F, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s.
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The analyses were well powered to detect the effects 
of treatment on spirometry, confirming 1-year spirometry 
findings in the studied trials9,10,12 and agreeing with results 
of other studies;13–15 in addition, the analyses showed a 
treatment effect 3 months after randomization. These data 
were supported by the PEF recordings from the daily diary 
cards, which confirmed earlier reports of a treatment effect 
being evident within 1 week of randomization.9 Statistically 
significant, although generally smaller, changes in lung func-
tion were seen as baseline FEV
1
 worsened. This accords with 
observations of the acute bronchodilator effects in COPD, 
with smaller relative and absolute increases in FEV
1
 as 
GOLD severity increases.17 This smaller response is likely 
to reflect the increased prevalence of tidal expiratory flow 
limitation in more severe COPD18 and points toward the 
importance of lung volume change, rather than spirometry in 
these circumstances. Although the absolute changes in lung 
function in our data were small, the improvements in terms of 
rescue medication and their relationship to improved symp-
tom scores were, if anything, greater in patients with worse 
baseline spirometry. This is important as we have shown that 
increased use of reliever medication is a marker for exacerba-
tion risk.19 The presence of a statistically significant change in 
all these outcomes suggests that, for a significant number of 
individuals, combination therapy offers worthwhile improve-
ments within 3 months of commencement across a range of 
clinically relevant measures.
This post hoc analysis has focused on changes in effi-
cacy measures at 3 months after initiation of treatment. The 
effects of combination therapy across a range of safety and 
tolerability measures have been previously reported in the 
original publications.9,10,12 In this pooled safety analysis, the 
observed rates of AEs, serious AEs, and deaths due to AEs 
were similar in the B/F group to that observed in the placebo 
group, consistent with the original individual studies,9,10,12 
while discontinuations due to AEs occurred less frequently in 
patients treated with B/F than those receiving placebo. Prior 
to the analysis, it was determined that when separated out 
and analyzed by disease severity, the number of individual 
types of events such as pneumonia would be too small for 
meaningful interpretation.
This study data have strengths and limitations. The study 
reports data from a large number of patients, covering a range 
of spirometric severity, and includes comparisons with pla-
cebo. Reductions in 3-month exacerbation rates have previ-
ously been reported in prospective studies and were 62% for 
B/F plus tiotropium versus tiotropium plus placebo10 and 36% 
for B/F versus formoterol.20 Although the current analysis 
was post hoc in terms of the primary study outcomes, it adds 
to the literature, as investigating the effect of an ICS/LABA 
combination at 3 months in different disease severities is 
novel. In one study that had been included in the analysis, all 
patients used tiotropium as a maintenance bronchodilator, and 
the lower exacerbation rates reported here at 3 months may 
reflect this.10 However, the behavior of patients in this study 
did not differ from those in the other two studies in which the 
baseline exacerbation rate was higher in the placebo arm.9,12 
In addition, data were not available on prior exacerbation 
history or Medical Research Council breathlessness score to 
use in the analysis by the current GOLD grouping.
This study considered only exacerbations that led to 
the use of oral corticosteroids (alone or in combination 
with antibiotics) and/or hospitalization or emergency room 
visits, a definition currently supported by the GOLD ini-
tiative and others. This could, however, identify a more 
steroid-responsive exacerbation type. Pooled diary card 
symptom scores could identify treatment effects21 but unlike 
more recent tools,22,23 they were not validated to identify 
exacerbations that did not require medical treatment. If 
we had been able to use this approach, it is likely that the 
number of events being identified would have been greater. 
Evidence from other studies suggests that the trend of such 
events would have been similar to those where patients had 
sought increases in treatment,24 and hence, these additional 
episodes might have allowed to draw the same conclusion 
with fewer patients.
Limitations
Other limitations include the number of patients who dropped 
out from the study, by both 3 and 12 months. This may have 
affected the accuracy of the results, including exacerbation 
rates. High dropout rates can confound the interpretation of 
randomized controlled trials and can be a common feature 
in trials involving patients with COPD, with some analyses 
reporting 27%–53% dropout.25 In addition, the moderate 
group in our analysis had airway reversibility of 10%–11% 
(% predicted). It is now recognized that COPD patients with 
moderate airflow obstruction show a greater absolute change 
in FEV
1
 post-bronchodilator than that seen in more severe 
disease.26 This contributes to the greater degree of revers-
ibility reported in analyses of moderate patients in clinical 
trials similar to this study. The entry criteria for the three 
studies included in this analysis are consistent with those of 
other clinical trials in the area and did not select patients on 
the basis of known reversibility to bronchodilators.
These data have implications for the use and evaluation 
of treatment in COPD. It was found that a measurable effect 
on COPD exacerbations (defined by symptoms necessitating 
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the addition of, or treatment with, oral or systemic corti-
costeroids) occurred within 3 months of randomization to 
the ICS/LABA combination in COPD patients who had 
experienced at least one exacerbation in the past year. This 
positive effect on exacerbation frequencies was paralleled by 
improved lung function, lower use of reliever medication, 
and fewer symptoms. Whether these changes in objective 
patient-reported outcomes can be used to predict a further 
course of events remains to be established at an individual 
patient level. However, they should reassure clinicians that 
treatment is effective across a range of endpoints, including 
exacerbation prevention, soon after initiation.
Conclusions
In conclusion, data from this study show that treatment with 
an ICS/LABA combination has important clinical impact 
irrespective of disease severity; these effects are evident 
within 3 months after the initiation of treatment.
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Table S3 Number (%) of patients who had an adverse event (AE) in any category in the 3-month budesonide/formoterol vs placebo 
pool (Welte et al, Calverley et al, and Szafranski et al studies)1,2,4
Category of AE Budesonide/formoterol
(n=791)
Placebo
(n=791)
any ae 275 (34.8) 269 (34.0)
serious aes 44 (5.6) 54 (6.8)
serious aes leading to death 3 (0.4) 3 (0.4)
serious aes not leading to death 41 (5.2) 51 (6.4)
Discontinuation of study treatment due to aes 46 (5.8) 91 (11.5)
Notes: Safety population includes all patients who received at least one dose of treatment. This table includes patients with AEs onset during randomized treatment. Patients 
with multiple events in the same category are counted only once in that category. Patients with events in .1 category are counted once in each of those categories.
Table S4 Number (%) of patients who had an adverse event (AE) in any category in the 12-month budesonide/formoterol vs placebo 
pool (Calverley et al and szafranski et al studies only)1,2
Category of AE Budesonide/formoterol
(n=462)
Placebo
(n=461)
any ae 284 (61.5) 270 (58.6)
serious aes 93 (20.1) 88 (19.1)
serious aes leading to death 10 (2.2) 10 (2.2)
serious aes not leading to death 85 (18.4) 80 (17.4)
Discontinuation of study treatment due to aes 81 (17.5) 119 (25.8)
Notes: Safety population includes all patients who received at least one dose of treatment. This table includes patients with AEs onset during randomized treatment. Patients 
with multiple events in the same category are counted only once in that category. Patients with events in .1 category are counted once in each of those categories.
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Figure S1 Proportion of patients with moderate-to-very-severe COPD who received B/F or placebo and who had zero, 1, 2, or $3 exacerbations over the 3-month study 
period.
Abbreviations: B/F, budesonide/formoterol; COPD, chronic obstructive pulmonary disease.
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Table S5 Number (%) of patients with most common adverse events (AEs) (frequency of $2% in any treatment group) in the 3-month 
budesonide/formoterol vs placebo pool (Welte et al, Calverley et al, and Szafranski et al studies)1,2,4
Preferred term Budesonide/formoterol
(n=791)
Placebo
(n=791)
Chronic obstructive pulmonary disease 56 (7.1%) 103 (13.0%)
nasopharyngitis 30 (3.8%) 26 (3.3%)
headache 12 (1.5%) 7 (0.9%)
Dysphonia 14 (1.8%) 0 (0.0%)
Pharyngitis 4 (0.5%) 7 (0.9%)
Pyrexia 9 (1.1%) 1 (0.1%)
Notes: This table includes patients with AEs onset during randomized treatment. Patients with multiple AEs coded to the same preferred term are counted only once for 
that preferred term.
Table S6 Number (%) of patients with most common adverse events (AEs) (frequency of $2% in any treatment group) in the 
12-month budesonide/formoterol vs placebo pool (Calverley et al and Szafranski et al studies only)1,2
Preferred term Budesonide/formoterol
(n=462)
Placebo
(n=461)
Chronic obstructive pulmonary disease 84 (18.2%) 125 (27.1%)
nasopharyngitis 42 (9.1%) 27 (5.9%)
headache 15 (3.2%) 10 (2.2%)
Pneumonia 14 (3.0%) 11 (2.4%)
Chest pain 16 (3.5%) 8 (1.7%)
Dyspnoea 8 (1.7%) 15 (3.3%)
Back pain 9 (1.9%) 9 (2.0%)
Muscle spasms 14 (3.0%) 4 (0.9%)
respiratory tract infection 10 (2.2%) 7 (1.5%)
Diarrhoea 9 (1.9%) 6 (1.3%)
Influenza 11 (2.4%) 2 (0.4%)
rhinitis 10 (2.2%) 3 (0.7%)
Insomnia 7 (1.5%) 5 (1.1%)
Myalgia 8 (1.7%) 3 (0.7%)
Dysphonia 9 (1.9%) 1 (0.2%)
Pharyngitis 5 (1.1%) 5 (1.1%)
Pyrexia 8 (1.7%) 2 (0.4%)
Dyspepsia 8 (1.7%) 1 (0.2%)
Vomiting 5 (1.1%) 1 (0.2%)
Notes: This table includes patients with AEs onset during randomized treatment. Patients with multiple AEs coded to the same preferred term are counted only once for 
that preferred term.
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